A comprehensive meta-analysis on safety outcomes reveals the novel potentials of SGLT2is, especially preventing respiratory diseases.

A meta-analysis published in Frontiers in Endocrinology suggests that sodium-glucose cotransporter-2 inhibitors (SGLT2is) may have positive effects on respiratory conditions such as chronic obstructive pulmonary disease (COPD), asthma, and pneumonia. The analysis evaluated safety outcomes from nine large-scale randomized controlled trials and found that SGLT2is were generally safe for various body systems, including the gastrointestinal system. However, they were associated with an increased risk of diabetic ketoacidosis. The findings suggest potential new applications for SGLT2is in the prevention and treatment of certain diseases, but further research is needed to confirm these findings. The text also references various medical studies and trials exploring the efficacy and safety of different medications for the treatment of diabetes, heart failure, and chronic kidney disease. These studies investigate the impact of these medications on cardiovascular and renal outcomes, glycemic control, and other biomarkers. Some studies also explore potential associations between SGLT2 inhibitors and adverse respiratory events, non-small cell lung cancer survival, tumor suppression, depression, and alleviation of anemia in patients with chronic kidney disease. [Extracted from the article]